The Dura Mater is the fibrous membrane that protects the brain and spinal cord while retaining cerebrospinal fluid (CSF). Dural repair is routinely required after head or spinal trauma, neurosurgical procedures, or tumour removal. A common complication is post-surgical CSF leakage, occurring in 4–32% of neurosurgeries depending on surgical site. Such leaks can lead to extended hospitalisation, reoperations, and infection, with associated costs ~ €11,000 per patient. Beyond the economic burden, these complications cause significant physical and emotional distress for patients.
Current dural repair solutions are limited: they are expensive, require time-consuming suturing, and fail to both ensure watertight sealing and promote regeneration. As a result, leak rates remain high and the risk of post-op complications persists.
Nurami’s ArtiFix: An Innovative Solution
ArtiFix will be the first 3-in-1 nanofiber-based adhesive patch for dural repair, combining:
1. Watertight sealing of wet tissue, preventing CSF leaks.
2. Strong adhesion to the surgical site without the need for sutures.
3. Natural healing promotion, via a porous nanofiber matrix that cues cell regeneration.
The adhesive nanofiber technology uniquely allows in-situ activation of functional groups, enabling application to wet tissue surfaces — a key advantage.
Project Pathway
The project aims to reduce CSF leakage rates from up to 32% to below 1%, while lowering procedural and overall healthcare costs. By eliminating the need for separate sealants and suturing, ArtiFix will reduce direct procedural costs by approximately €280 per surgery (~30%). For a mid-sized medical centre performing 2,000 neurosurgeries annually, savings are projected at €2.56M per year.
The initial commercial pathway involves a soft launch in Centres of Excellence (CoEs) across the EU and US, leveraging key opinion leaders (KOLs) and clinical case studies to accelerate adoption. Data generated will support broader market penetration through a hybrid in-house and distributor sales model. The product initially targets high-leakage and hard-to-suture cases — spinal, infratentorial cranial, and trauma supratentorial repair — with potential expansion to the €12.5B soft tissue repair market
Projected Impact
The clinical and economic impact is substantial:
• Clinical: Improved patient safety, fewer complications, faster recovery, and reduced need to reoperate.
• Economic: Significant direct and indirect healthcare savings for hospitals and systems.
• Market: First-mover advantage in a global dural repair segment with unmet needs, enabling rapid scale-up.
Healthcare systems in the EU and US are under increasing pressure to reduce hospital stays and improve surgical outcomes while controlling costs. This aligns with policy and procurement trends favouring innovative solutions that combine improved clinical efficacy with cost savings. ArtiFix supports these goals, offering an evidence-based, surgeon-friendly product that can be rapidly integrated into standard neurosurgical practice.
